Baseline characteristics of patients who received standard and prebiotic EN
| . | Standard EN, n = 10 . | Prebiotic EN, n = 20 . | P value . |
|---|---|---|---|
| Age, median (range), y | 52 (20-70) | 62 (20-69) | .328 |
| Sex, n (%) | .431 | ||
| Male | 6 (60) | 15 (75) | |
| Female | 4 (40) | 5 (25) | |
| Diagnosis, n (%) | .151 | ||
| AML | 1 (10) | 8 (40) | |
| ALL | 1 (10) | 4 (20) | |
| MDS | 1 (10) | 4 (20) | |
| SAA | 2 (20) | 2 (10) | |
| Lymphoproliferative disorders (T-cell lymphoma, HL + DLBCL, and aAITL) | 2 (20) | 1 (5) | |
| Myeloproliferative neoplasm (CML, CMML, and MF) | 3 (30) | 1 (5) | |
| Donor type, n (%) | .580 | ||
| Volunteer unrelated donor | 6 (60) | 9 (45) | |
| Sibling | 2 (20) | 8 (40) | |
| Haploidentical | 2 (20) | 3 (15) | |
| Conditioning, n (%) | .383 | ||
| Cy-TBI | 1 (10) | 3 (15) | |
| Fludarabine-melphalan | 6 (60) | 11 (55) | |
| Melphalan-fludarabine-TBI, PTCy | 0 | 3 (15) | |
| Fludarabine-TBI, PTCy | 0 | 1 (5) | |
| Cy-ATG | 1 (10) | 2 (10) | |
| Other | 2 (20) | 0 | |
| Infection preconditioning,∗ n (%) | 1 (10) | 0 | .333 |
| Antibiotic preconditioning, n (%) | .125 | ||
| Pneumocystis jirovecii prophylaxis | 4 (40) | 10 (50) | |
| Other | 2 (20) | 0 | |
| Duration of antibiotics before conditioning (n = 16), n (%) | .125 | ||
| <1 week | 0 | 1 (10) | |
| Several weeks | 2 (33) | 0 | |
| Several months | 4 (67) | 9 (90) | |
| Weight on admission, median (Q1-Q3), kg | 92 (89-105) | 82 (69-95) | .328 |
| BMI on admission, median (Q1-Q3), kg/m2 | 28 (27-31) | 27 (24-29) | .448 |
| SGA on admission, n (%) | 1.0 | ||
| A, well nourished | 10 (100) | 19 (95) | |
| B, malnourished | 0 | 1 (5) | |
| Oral nutritional intake before conditioning (n = 9; n = 19)∗ | |||
| Energy, median (Q1-Q3), kJ/d | 10 957 (10 100-11 566) | 7 400 (6 674-9 359) | .054 |
| Protein, median (Q1-Q3), g/d | 109 (92-115) | 97 (78-110) | .357 |
| Fiber, median (Q1-Q3), g/d | 16 (14-20) | 19 (17-23) | .188 |
| Estimated energy requirements, median (Q1-Q3), kJ/d | 9 150 (7 700-9 500) | 8 200 (6 850-9 350) | .373 |
| Estimated protein requirements, median (Q1-Q3), g/d | 92 (75-95) | 82 (69-94) | .397 |
| . | Standard EN, n = 10 . | Prebiotic EN, n = 20 . | P value . |
|---|---|---|---|
| Age, median (range), y | 52 (20-70) | 62 (20-69) | .328 |
| Sex, n (%) | .431 | ||
| Male | 6 (60) | 15 (75) | |
| Female | 4 (40) | 5 (25) | |
| Diagnosis, n (%) | .151 | ||
| AML | 1 (10) | 8 (40) | |
| ALL | 1 (10) | 4 (20) | |
| MDS | 1 (10) | 4 (20) | |
| SAA | 2 (20) | 2 (10) | |
| Lymphoproliferative disorders (T-cell lymphoma, HL + DLBCL, and aAITL) | 2 (20) | 1 (5) | |
| Myeloproliferative neoplasm (CML, CMML, and MF) | 3 (30) | 1 (5) | |
| Donor type, n (%) | .580 | ||
| Volunteer unrelated donor | 6 (60) | 9 (45) | |
| Sibling | 2 (20) | 8 (40) | |
| Haploidentical | 2 (20) | 3 (15) | |
| Conditioning, n (%) | .383 | ||
| Cy-TBI | 1 (10) | 3 (15) | |
| Fludarabine-melphalan | 6 (60) | 11 (55) | |
| Melphalan-fludarabine-TBI, PTCy | 0 | 3 (15) | |
| Fludarabine-TBI, PTCy | 0 | 1 (5) | |
| Cy-ATG | 1 (10) | 2 (10) | |
| Other | 2 (20) | 0 | |
| Infection preconditioning,∗ n (%) | 1 (10) | 0 | .333 |
| Antibiotic preconditioning, n (%) | .125 | ||
| Pneumocystis jirovecii prophylaxis | 4 (40) | 10 (50) | |
| Other | 2 (20) | 0 | |
| Duration of antibiotics before conditioning (n = 16), n (%) | .125 | ||
| <1 week | 0 | 1 (10) | |
| Several weeks | 2 (33) | 0 | |
| Several months | 4 (67) | 9 (90) | |
| Weight on admission, median (Q1-Q3), kg | 92 (89-105) | 82 (69-95) | .328 |
| BMI on admission, median (Q1-Q3), kg/m2 | 28 (27-31) | 27 (24-29) | .448 |
| SGA on admission, n (%) | 1.0 | ||
| A, well nourished | 10 (100) | 19 (95) | |
| B, malnourished | 0 | 1 (5) | |
| Oral nutritional intake before conditioning (n = 9; n = 19)∗ | |||
| Energy, median (Q1-Q3), kJ/d | 10 957 (10 100-11 566) | 7 400 (6 674-9 359) | .054 |
| Protein, median (Q1-Q3), g/d | 109 (92-115) | 97 (78-110) | .357 |
| Fiber, median (Q1-Q3), g/d | 16 (14-20) | 19 (17-23) | .188 |
| Estimated energy requirements, median (Q1-Q3), kJ/d | 9 150 (7 700-9 500) | 8 200 (6 850-9 350) | .373 |
| Estimated protein requirements, median (Q1-Q3), g/d | 92 (75-95) | 82 (69-94) | .397 |
AITL, angioimmunoblastic T-cell lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; BMI, body mass index; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; Cy, cyclophosphamide; HL + DLBCL, Hodgkin lymphoma and diffuse large B-cell lymphoma; MDS, myelodysplastic syndromes; MF, myelofibrosis; PTCy, posttransplant cyclophosphamide; SAA, severe aplastic anemia; SGA, subjective global assessment; TBI, total body irradiation; Q1/Q3, lower quartile/upper quartile.
One patient from each group did not provide food diaries of oral intake before conditioning.